Oncology

Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
IND-enabling
Dual-MEK inh
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

95%
MEK-io
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

73%
RASi
IMM-1811901
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

62%
pan-KRAS4B inh
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

50%
Covalent-MEK
IMM-2019611
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

50%
PI3K inh
IMM-1011213
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

33%

Neuroscience

IMM-ALL-03
Alzheimer's Disease (Subset A)
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

36%
IMM-ALL-01
Alzheimer's Disease (Subset A)
Target ID
Hit-ID
Hit-to-Lead
Lead-ID
Lead Opt
Pre-IND

Title

33%

More than half of all tumors rely on inappropriate activation of the RAS/RAF/MEK pathway, yet existing drugs targeting this pathway are limited by toxicity or are narrowly focused on subpopulations with specific mutations. Immuneering’s novel drug candidates spare healthy normal cells by modulating cell signaling dynamics to selectively impact tumor cells.

Oncology – Select Therapies

  IMM-1-104

IMM-1611441 BODY showing digestive systemImmuneering is developing its lead candidate IMM-1-104 as a dual inhibitor of MEK and a related target, to inhibit this important pathway driving the growth of many tumors while avoiding the feedback loop that causes many patients to develop resistance to traditional MEK inhibitors. By targeting MEK in a novel way, our preclinical models have demonstrated greater durability with reduced overall toxicity.

Our Clinical Candidate, IMM-1-104, is in IND-enabling studies.

  IMM-2019611

IMM-2019611 BODY showing skeletonImmuneering is developing IMM-2019611 as a differentiated inhibitor of the MAPK signaling pathway. The MAPK pathway is a central signaling cascade involved in cell proliferation, cell growth, malignant transformation and drug resistance. Increased expression of this pathway is associated with a poor prognosis in cancers.5

IMM-2019611 is currently in lead identification stage of drug development.

  IMM-1811900

IMM-1811900 BODY showing organsImmuneering is developing IMM-1811900 for KRAS-driven cancers including pancreatic, colorectal and lung cancers. KRAS is the most commonly mutated of the RAS isoforms and represents an attractive target for treatment given its ubiquity, central role as a driver mutation and association with poor prognosis. KRAS mutations occur in approximately 25 percent of all human cancers, including more than 90 percent of pancreatic cancers, 35 to 45 percent of colorectal cancers and approximately 25 percent of lung cancers.6 Activating mutations of KRAS lead to cell transformation and increased resistance to chemotherapy. Currently, no effective treatments exist that target mutant variants of KRAS.

IMM-1811900 is currently in hit-to-lead stage of drug development.

For most Alzheimer’s patients, there is no clear trajectory of disease progression or worsening symptoms. In fact, even clinical presentation can be widely different from individual to individual, suggesting that Alzheimer’s is less of a disease and more of a syndrome. Integrating brain gene expression and AD marker data offers the potential to stratify patients into subgroups with unique biology and identify targets specific to these subgroups.